Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Ovarian Neoplasms 9 Lung Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Squamous Cell Carcinoma of Head and Neck 7 Sarcoma 7 Colorectal Neoplasms 7 Prostatic Neoplasms 6 Fallopian Tube Neoplasms 6 Neoplasm Metastasis 5 Lymphoma 5 Head and Neck Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Uterine Cervical Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Osteosarcoma 4 Neoplasms 4 Leukemia, Myeloid, Acute 4 Central Nervous System Neoplasms 4 Burkitt Lymphoma 4 Stomach Neoplasms 3 Sezary Syndrome 3 Salivary Gland Neoplasms 3 Rhabdoid Tumor 3 Rectal Neoplasms 3 Pain 3 Neuroectodermal Tumors, Primitive, Peripheral 3 Mycosis Fungoides 3 Melanoma 3 Lymphoma, T-Cell, Cutaneous 3

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × NETWORK × Serotonin Syndrome × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡